Drug Interaction Study of PSI-7977 and Antiretroviral Therapy(ART) Combinations in Human Immunodeficiency Virus and Hepatitis C Virus (HIV/HCV) Co-infected Patients.

This is a drug interaction study between PSI-7977 and antiretroviral therapy (ART) combinations of Efavirenz, Tenofovir and Emtricitabine; Efavirenz, Zidovudine and Lamivudine; Atazanavir/r, Tenofovir and Emtricitabine; in patients co-infected with HIV and HCV. This is an open-label study of approximately 24 healthy HIV/HCV co-infected patients. The study consists of 3 cohorts of 8 patients in each cohort. Patients will be treated with PSI-7977 for 7 days in combination with their ART regimen that the subject has been receiving to manage their HIV infection.